BIOMAT Database Logo BIOMAT Database Logo

Selective alpha-blockade versus angiotensin-converting enzyme inhibition as initial antihypertensive therapy. Effects on circulating lipoproteins. 1989

M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Department of Medicine, University of California, San Diego.

This study evaluated the overall efficacy and safety of two specific vasodilators--the alpha-blocker prazosin and the angiotensin-converting enzyme inhibitor captopril--in the treatment of mild-to-moderate essential hypertension. Because the current approach to antihypertensive treatment should consider possible drug-related changes in circulating lipid fractions, the present study investigated the effects of these two drugs on lipid parameters as well. Used either as single agents or in combination with hydrochlorothiazide, both drugs effectively reduced high blood pressure. Neither drug had adverse effects on the lipid profile in general, although there were significant differences between the effects of prazosin and captopril on total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534

Related Publications

M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Angiotensin converting enzyme inhibition and calcium channel blockade as primary antihypertensive therapy.
December 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Effects of angiotensin-converting enzyme inhibition versus conventional antihypertensive therapy on the glomerular filtration rate.
January 1995, Cardiology,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Angiotensin-converting enzyme inhibition versus blockade of the renin-angiotensin system.
December 1989, The American journal of medicine,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Acute antihypertensive effect of angiotensin converting enzyme inhibition and calcium entry blockade.
January 1987, Journal of cardiovascular pharmacology,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
The antihypertensive effects of sodium nitrite are not associated with circulating angiotensin converting enzyme inhibition.
August 2014, Nitric oxide : biology and chemistry,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
April 1999, Clinical pharmacology and therapeutics,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Angiotensin-converting enzyme inhibitors in antihypertensive therapy.
April 2000, Current hypertension reports,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension.
January 1996, Journal of cardiovascular pharmacology,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition.
September 1996, Journal of hypertension,
M A Takiyyuddin, and J H Cervenka, and T Dinh, and J L Witztum, and D T O'Connor
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
February 2012, Journal of the American Society of Nephrology : JASN,
Copied contents to your clipboard!